Resource Type

Journal Article 1

Year

2019 1

Keywords

cirrhosis 1

hepatic stellate cell 1

palosuran 1

portal hypertension 1

urotensin II 1

Search scope:

排序： Display mode:

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl

Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 398-408 doi: 10.1007/s11684-019-0689-5

Abstract: To investigate the therapeutic effects of urotensin II receptor (UT) antagonist palosuran on rats withCompared with the vehicle-treated cirrhotic rats, treatment with palosuran can reduce the portal pressureHowever, treatment with palosuran can increase MMP-13/TIMP-1, p-vasodilator-stimulated phosphoproteinMMP-13/TIMP-1, COL-I, and p-VASP are inhibited after palosuran treatment.Our data indicate that long-term administration of palosuran can decrease PP in cirrhosis, which results

Keywords： portal hypertension     cirrhosis     urotensin II     palosuran     hepatic stellate cell    

HTML PDF Collect

Title Author Date Type Operation

Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl

Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang

Journal Article